Cargando…
SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19
Over the past two years, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused hundreds of millions of infections, resulting in an unprecedented pandemic of coronavirus disease 2019 (COVID-19). As the virus spreads through the population, ongoing mutations and adaptations are b...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504858/ https://www.ncbi.nlm.nih.gov/pubmed/36146616 http://dx.doi.org/10.3390/vaccines10091538 |
_version_ | 1784796323227107328 |
---|---|
author | Liang, Hong-Yu Wu, Yuyan Yau, Vicky Yin, Huan-Xin Lowe, Scott Bentley, Rachel Ahmed, Mubashir Ayaz Zhao, Wenjing Sun, Chenyu |
author_facet | Liang, Hong-Yu Wu, Yuyan Yau, Vicky Yin, Huan-Xin Lowe, Scott Bentley, Rachel Ahmed, Mubashir Ayaz Zhao, Wenjing Sun, Chenyu |
author_sort | Liang, Hong-Yu |
collection | PubMed |
description | Over the past two years, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused hundreds of millions of infections, resulting in an unprecedented pandemic of coronavirus disease 2019 (COVID-19). As the virus spreads through the population, ongoing mutations and adaptations are being discovered. There is now substantial clinical evidence that demonstrates the SARS-CoV-2 variants have stronger transmissibility and higher virulence compared to the wild-type strain of SARS-CoV-2. Hence, development of vaccines against SARS-CoV-2 variants to boost individual immunity has become essential. However, current treatment options are limited for COVID-19 caused by the SARS-CoV-2 variants. In this review, we describe current distribution, variation, biology, and clinical features of COVID-19 caused by SARS-CoV-2 variants (including Alpha (B.1.1.7 Lineage) variant, Beta (B.1.351 Lineage) variant, Gamma (P.1 Lineage) variant, Delta (B.1.617.2 Lineage) variant, and Omicron (B.1.1.529 Lineage) variant and others. In addition, we review currently employed vaccines in clinical or preclinical phases as well as potential targeted therapies in an attempt to provide better preventive and treatment strategies for COVID-19 caused by different SARS-CoV-2 variants. |
format | Online Article Text |
id | pubmed-9504858 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95048582022-09-24 SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19 Liang, Hong-Yu Wu, Yuyan Yau, Vicky Yin, Huan-Xin Lowe, Scott Bentley, Rachel Ahmed, Mubashir Ayaz Zhao, Wenjing Sun, Chenyu Vaccines (Basel) Review Over the past two years, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused hundreds of millions of infections, resulting in an unprecedented pandemic of coronavirus disease 2019 (COVID-19). As the virus spreads through the population, ongoing mutations and adaptations are being discovered. There is now substantial clinical evidence that demonstrates the SARS-CoV-2 variants have stronger transmissibility and higher virulence compared to the wild-type strain of SARS-CoV-2. Hence, development of vaccines against SARS-CoV-2 variants to boost individual immunity has become essential. However, current treatment options are limited for COVID-19 caused by the SARS-CoV-2 variants. In this review, we describe current distribution, variation, biology, and clinical features of COVID-19 caused by SARS-CoV-2 variants (including Alpha (B.1.1.7 Lineage) variant, Beta (B.1.351 Lineage) variant, Gamma (P.1 Lineage) variant, Delta (B.1.617.2 Lineage) variant, and Omicron (B.1.1.529 Lineage) variant and others. In addition, we review currently employed vaccines in clinical or preclinical phases as well as potential targeted therapies in an attempt to provide better preventive and treatment strategies for COVID-19 caused by different SARS-CoV-2 variants. MDPI 2022-09-16 /pmc/articles/PMC9504858/ /pubmed/36146616 http://dx.doi.org/10.3390/vaccines10091538 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Liang, Hong-Yu Wu, Yuyan Yau, Vicky Yin, Huan-Xin Lowe, Scott Bentley, Rachel Ahmed, Mubashir Ayaz Zhao, Wenjing Sun, Chenyu SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19 |
title | SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19 |
title_full | SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19 |
title_fullStr | SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19 |
title_full_unstemmed | SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19 |
title_short | SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19 |
title_sort | sars-cov-2 variants, current vaccines and therapeutic implications for covid-19 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504858/ https://www.ncbi.nlm.nih.gov/pubmed/36146616 http://dx.doi.org/10.3390/vaccines10091538 |
work_keys_str_mv | AT lianghongyu sarscov2variantscurrentvaccinesandtherapeuticimplicationsforcovid19 AT wuyuyan sarscov2variantscurrentvaccinesandtherapeuticimplicationsforcovid19 AT yauvicky sarscov2variantscurrentvaccinesandtherapeuticimplicationsforcovid19 AT yinhuanxin sarscov2variantscurrentvaccinesandtherapeuticimplicationsforcovid19 AT lowescott sarscov2variantscurrentvaccinesandtherapeuticimplicationsforcovid19 AT bentleyrachel sarscov2variantscurrentvaccinesandtherapeuticimplicationsforcovid19 AT ahmedmubashirayaz sarscov2variantscurrentvaccinesandtherapeuticimplicationsforcovid19 AT zhaowenjing sarscov2variantscurrentvaccinesandtherapeuticimplicationsforcovid19 AT sunchenyu sarscov2variantscurrentvaccinesandtherapeuticimplicationsforcovid19 |